Australian study of the effects of strict potassium restriction on nerve function in patients with chronic kidney disease

Not Applicable

Completed

• Conditions: Stage 3-4 Chronic kidney disease; Neuropathy; Neurological - Other neurological disorders; Renal and Urogenital - Kidney disease

• Registration Number: ACTRN12610000538044
• Lead Sponsor: Dr Arun Krishnan

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-07-05
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

History of Chronic Kidney Disease (stage 3 or 4), as defined by the estimated glomerular filtration rate.

Monthly attendance for clinical care at Kidney Care Centre, Prince of Wales Hospital.

Able to provide informed consent

Exclusion Criteria

Current or past history of dialysis therapy or previous renal transplantation.

Cognitively impaired

Unable to speak and/or understand English

Pregnant

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The development of neuropathy assessed by the total neuropathy score (0-28 with a higher score indicating worse neuropathy) and the neuropathy symptom score (0-no neuropathy to 3-disabling neuropathy)[Every 6 months after randomisation for 2 years]

Secondary Outcome Measures

Name	Time	Method
Peripheral nerve excitability parameters (threshold electrotonus, superexcitability)[Every 6 months after randomisation for 2 years];Sural nerve sensory amplitude (uV) as measured by routine nerve conduction equipment[Every 6 months after randomisation for 2 years];Health related quality of life using the physical function subscale of SF36[Every 6 months after randomisation for 2 years];Handgrip strength by dynamometry[Every 6 months after randomisation for 2 years];Timed 6m walk[Every 6 months after randomisation for 2 years]